Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, Arturo Casadevall, Fabrizio Maggi, Guido Antonelli
Topics & Concepts
PharmacokineticsMedicineDiscontinuationRitonavirPharmacodynamicsClinical trialPharmacologyObservational studyCoronavirus disease 2019 (COVID-19)PharmacoeconomicsDrug developmentRandomized controlled trialInternal medicineIntensive care medicineDrugVirologyVirusViral loadAntiretroviral therapyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing